PTEN and mesothelioma: Previous studies have suggested that aberrant activation of PI3-K/AKT/mTOR signaling due to down-regulation or complete loss of PTEN or an alternative mechanism of PIK3CA mutation, is a potential therapeutic target in LPS and mesothelioma [2, 13, 14, 37, 38].